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2576Elimination of All
Inducible Ventricular
Tachycardias as the
Endpoint for AblationWe read with interest the paper by Yokokawa et al.
(1) and wanted to congratulate the authors for its
valuable contributions. The ideal endpoint of ven-
tricular tachycardia (VT) ablation procedures has not
been deﬁnitively established (2,3). This study pro-
vides relevant data suggesting that elimination of all
inducible VT could serve as a reliable endpoint.
Nevertheless there are some concerns that we would
like to address.
First, assumption of causality between 2 observa-
tions (i.e., persistence of inducibility and increased
mortality) can only be deduced from randomized
studies. In fact, it may be that post-procedure VT
inducibility could simply be a marker of a worse
prognosis, reﬂecting differences in scar extension and
transmurality.
Second, the analysis is performed by comparing 2
rather artiﬁcial and unbalanced groups of patients:
Patients who were noninducible post-ablation (also
including in this group patients not inducible pre-
ablation) with another group comprising patients
who were inducible post-ablation and patients not
tested for inducibility. These latter patients (who
were probably sicker patients in poor clinical condi-
tion that precluded post-ablation VT induction) had
an unadjusted nonsigniﬁcant trend toward increased
mortality (23% excess, p ¼ 0.28). There was a higher
proportion of patients receiving amiodarone (56% vs.
37%, p < 0.0001) in the inducible group. Amiodarone
is associated with increased mortality in patients in
functional classes III to IV (4). An analysis focusing
on comparing inducible with noninducible patients
(excluding patients who were not tested) is not
presented in the text nor as supplemental material
and may provide a less biased comparison of both
groups.
Could pursuit of this endpoint modify the out-
come of the procedure? Implantable cardioverter-
deﬁbrillator shocks are associated with increased
mortality. It can thus be reasoned that pursuing
VT-inducibility suppression could lead to multiple VT
inductions and shocks that could themselves have a
negative impact on mortality. How many shocks were
delivered to patients in whom VT was not sup-
pressed? Was there a limit for VT inductions? We
are concerned that patients with no endocardialsubstrate could receive multiple shocks in the pursuit
of an unattainable objective.
In our opinion, this study does not provide sufﬁ-
cient evidence to support VT inducibility suppression
as an end point. Such an ablation strategy could in-
crease the risk of complications due to lengthening
the procedure and the need for repeated VT induction
and cardioversion (5). Randomized studies comparing
complete eliminations of late potentials versus VT
inducibility suppression are required to deﬁne the
optimal ablation procedure.Pablo M. Ruiz Hernandez, PhD, MD
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1009–17.REPLY: Elimination of All Inducible
Ventricular Tachycardias as the
Endpoint for AblationDr. Hernandez and colleagues bring up several
interesting issues about our paper that was recently
published in the Journal. The association of
decreased mortality in the setting of noninducibility
was ﬁrst identiﬁed in a meta-analysis (1). Because the
studies included in the meta-analysis failed to correct
for confounding factors (e.g., ejection fraction, heart
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2577failure status, and other comorbidities), we wanted to
correct for these factors. Our data conﬁrmed the as-
sociation between decreased mortality and non-
inducibility, even when corrected for confounding
factors. We agree that the study design needed to
answer the question deﬁnitively is a randomized
study. This likely will not happen any time soon due
to the required number of patients that will need to
be enrolled, and therefore the data provided will
likely remain the best level of evidence in favor of the
association that we demonstrated.
Their second point addresses 2 subpopulations that
were included in the comparison: patients who were
noninducible to start with and patients in whom
programmed stimulation was not performed. As
indicated in the paper, exclusion of either of the
groups did not change the results of noninducibility
being associated with a lower mortality.
Third, it is correct that the patients who remained
inducible were more likely to be discharged on
amiodarone. The rate of amiodarone therapy at
discharge is signiﬁcantly higher in those with induc-
ible ventricular tachycardia (VT) than noninducible
VT. However, we only have data on treatment at
discharge and not during follow-up. Therefore, we
did not include the therapy as a covariate because it is
the more likely choice of treatment at discharge in
patients with inducible VT and thus is correlated with
our primary exposure variable of interest. However,
we did an additional analysis and obtained a hazard
ratio for noninducibility adjusting for the treatment.
In short, noninducibility post-ablation, although
reduced in magnitude, remained predictive of sur-
vival and signiﬁcant at 0.79 (95% conﬁdence interval:
0.65 to 0.95; p ¼ 0.01).
Several more questions follow that go beyond the
scope of the manuscript: Assessing whether the
endpoint of a procedure is reached can be difﬁcult and
may require several attempts at programmed stimu-
lation. Aggressive programmed stimulationmaynot be
appropriate depending on a patient’s hemodynamic
status. We have no data on how many implantable
cardioverter-deﬁbrillator shocks were allowed during
the testing at the conclusion of the procedure, nor
whether in some labs there was a limit of VT
inductions.
There are data indicating that elimination of late
potentials in addition to noninducibility improvesoutcome (2). This, however, was not the question that
we were trying to answer. Our question was a simple
one: Can noninducibility be used as a predictor of
outcomes? On the basis of our data, this indeed
appears to be the case.
At this point in time, our data provide the best
evidence available to target all inducible VTs.Miki Yokokawa, MD
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